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A B S T R A C T   
COVID-19 infection causes considerable morbidity and mortality, especially to those who are aged, have impaired renal function and are obese. We propose to 
examine the potential utility of oral activated charcoal with the hypothesis that such treatment would lower absorption of microbiome derived toxins and ameliorate 
systemic oxidant stress and inflammation.  
Background to hypothesis 
While coronaviruses have been known to cause potentially serious 
disease for ½ a century [1], COVID-19 has created a pandemic with 
adverse health consequences beyond the experiences of those people 
living today. As of July 14, 2020, approximately 13 million people have 
been infected with at least 570,000 dying from this disease and its 
complications [2]. Interestingly, the range of signs and symptoms 
ranges from those who have essentially no symptoms to those with fatal 
disease. It appears that age, renal dysfunction and obesity are amongst 
the most important risk factors for serious or fatal COVID-19 infection  
[3,4]. While there are multiple mechanisms by which this virus can 
injure hosts, it appears that increases in systemic cytokines and wide-
spread inflammation may play an important role [5]. 
Our research group has focused on the role that adipocytes play in the 
pathophysiology of metabolic and CV disease. In particular, we have 
noted that in experimental models of these diseases, the redox state 
within adipocytes has profound consequences to systemic oxidant stress, 
inflammation and disease phenotype [6–9]. We have specifically iden-
tified that products derived from tyrosine and tryptophan which are 
produced by the intestinal microbiome, specifically p-cresyl sulfate and 
indoxyl sulfate can directly cause oxidant stress in adipocytes [10]. These 
substances are excreted by the kidney and are known to accumulate in 
the plasma with impaired renal function [11]. Some workers have hy-
pothesized that the symptoms of uremia itself can be modulated by use of 
oral activated charcoal to lower absorption of these microbiome products  
[12]. Experimental data also support the concept that uremia potentiates 
sepsis and that oral activate charcoal can attenuate this [13]. 
On this background, the adipocyte is a known target for the virus  
[14], and as people age there are statistically likely decreases in renal 
function and increases in visceral adipocity [15]. There are data sug-
gesting that the virus can induce oxidative stress in adipocytes [16] and 
this oxidative stress can upregulate the expression of the ACE-2 protein  
[17], the putative receptor for COVID-19. In short, the elderly likely have 
increases in the circulating concentrations of these potentially toxic 
substances as well as the adipocyte mass which responds to them [16]. 
Hypothesis 
Administration of activated charcoal has been shown to be well 
tolerated when administered to a patients with renal dysfunction  
[18,19]. This activated charcoal has also been shown to effectively 
decrease circulating levels of p-cresyl sulfate and indoxyl sulfate [13]. 
In addition to its ability to scavenge these microbiome derived toxins, 
activated charcoal may also have non-specific absorptive properties 
that blunt inflammatory responses to [20] or possibly inactivate viruses  
[21]. Certainly, COVID-19 infection may directly involve the gastro-
intestinal tract in both human and bat [22]. Given that the potential 
toxicity of oral activated charcoal is so limited, we propose that an 
investigation of this coal-derived substance, widely available in the 
“mountain” state of WV, to potentially attenuate these adverse out-
comes be explored as definitive work seeking effective antivirals and 
development of a vaccine continues. A schematic summarizing this 
hypothesis is shown in Fig. 1. 
To test this hypothesis, we would suggest first a proof of concept 
study where a relatively small group of patients at high risk for COVID- 
19 complications are given activated charcoal at doses similar to that 
used in previous renal failure studies [18,19] when the diagnosis is first 
made. Cytokine levels, concentrations of indoxyl sulfate and p-cresyl 
sulfate along with evidence for systemic oxidant stress (e.g., protein 
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T
carbonylation) and inflammation would be serially monitored. Should 
preliminary outcomes be improved with this strategy, a randomized, 
prospective blinded study should be performed prior to large scale 
adaptation of this treatment strategy. 
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Fig. 1. Schema demonstrating intestinal microbiome-induced activation of Na/K-ATPase oxidant amplification loop in adipocytes exacerbating inflammation in 
COVID-19 infections. The microbiome causes increases in indoxyl sulfate (IS) and p-cresyl sulfate (PCS) absorption which, in turn, activate Na/K-ATPase signaling. 
This results in feed-forward amplification of ROS and cytokine production along with an alteration in the adipocyte phenotype. These ROS also increase ACE2 
expression, facilitating COVID-19 adipocyte infection which exacerbates this process. These effects would be attenuated by activated charcoal effecting decreases in 
microbiome-derived IS and PCS absorption. 
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